RARE News and Press, Ultragenyx Pharmaceutical Inc. From 11/01/23

2023-11-01 13:17:04 ET More on Ultragenyx Pharmaceutical Ultragenyx: Market Expectations Revised Lower, Awaiting Clinical Trial Catalysts (Rating Downgrade) Ultragenyx Pharmaceutical prices $300 million securities offering Seeking Alpha’s Quant Rating on Ultra...

NOVATO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...

NOVATO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced the closing of its previously announced underwritten pu...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is one of today's top gainers. The company's shares are currently up 8.79% on the day to $34.52. Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel pr...

2023-10-19 06:36:22 ET More on Ultragenyx Pharmaceutical Ultragenyx: Market Expectations Revised Lower, Awaiting Clinical Trial Catalysts (Rating Downgrade) Seeking Alpha’s Quant Rating on Ultragenyx Pharmaceutical Historical earnings data for Ultragenyx Pharm...

NOVATO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced the pricing of its underwritten public offering of 8,33...

2023-10-18 10:00:01 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further...

2023-10-17 16:07:13 ET More on Ultragenyx Pharmaceutical Ultragenyx: Market Expectations Revised Lower, Awaiting Clinical Trial Catalysts (Rating Downgrade) Seeking Alpha’s Quant Rating on Ultragenyx Pharmaceutical Historical earnings data for Ultragenyx Pharm...

Treatment with setrusumab (UX143) for at least 6 months resulted in 67% reduction in annualized fracture rate in patients with OI in Phase 2/3 Orbit study Quantitative data from the Phase 1/2 study of GTX-102 for AS show clinically meaningful improvements in multiple domains as compared...

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET NOVATO, Cal...